Nuclear Medicine and Biology
Volume 35, Issue 3 , Pages 273-279 , April 2008

Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines

  • Amy L. Vāvere

      Affiliations

    • Division of Radiological Sciences, Washington University School of Medicine, St. Louis, MO 63110, USA
    • ,
  • Jason S. Lewis

      Affiliations

    • Division of Radiological Sciences, Washington University School of Medicine, St. Louis, MO 63110, USA
    • Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA
    • Corresponding Author InformationCorresponding author. Mallinckrodt Institute of Radiology, Washington University School of Medicine, Campus Box 8225, St. Louis, MO 63110, USA. Tel.: +1 314 362 4696; fax: +1 314 362 9940.

Received 9 August 2007 ,Revised 29 November 2007 ,Accepted 30 November 2007.

References 

  1. Brown JM. The hypoxic cell: a target for selective cancer therapy—eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1999;59:5863–5870
  2. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KSC, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006;82:699–757
  3. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266–276
  4. Crabtree HG, Cramer W. The action of radium on cancer cells I, II. Some factors determining the susceptibility of cancer cells to radium. Proc Royal Soc Biol Sci. 1933;113:238–250
  5. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:638–648
  6. Tannock I, Guttman P. Responses of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br J Cancer. 1981;42:245–248
  7. Teicher BA, Holden SA, Al-Achi SA, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 1990;50:3339–3344
  8. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56:941–943
  9. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988;14:831–838
  10. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005;77:18–24
  11. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiologic Clin N Am. 2005;43:169–187
  12. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995;22:265–280
  13. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245–2252
  14. Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, et al. [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30:695–704
  15. Cherk MH, Foo SS, Poon AM, Knight SR, Murone C, Papenfuss AT, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET. J Nucl Med. 2006;47:1921–1926
  16. Piert M, Machulla H-J, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxic-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46:106–113
  17. Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A, et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol. 2003;30:317–326
  18. Souvatzoglou M, Grosu AL, Roper B, Krause BJ, Beck R, Reischl G, et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging. 2007;34:1566–1575
  19. Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. 2007;43:4893–4902
  20. Dearling JLD, Lewis JS, Mullen GED, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med. 1998;25:788–792
  21. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155–1160
  22. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response—a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233–1238
  23. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844–850
  24. Dietz DW, Dehdashti FD, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum. 2008;[in press]
  25. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM. J Nucl Med. 2008;49:201–205
  26. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40:177–183
  27. Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol. 2005;32:623–630
  28. O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, pO2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493–1502
  29. Vavere AL, Kridel SJ, Wheeler FB, Lewis JS. 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med. 2008;49:327–334
  30. Wakil SJ. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry. 1989;28:4523–4530
  31. Myers RB, Oelschlager DK, Weiss HL, Frost AR, Grizzle WE. Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence. J Urol. 2001;165:1027–1032
  32. Hochachka PW, Rupert JL, Goldenberg L, Gleave M, Kozlowski P. Going malignant: the hypoxia–cancer connection in the prostate. BioEssays. 2002;24:749–757
  33. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margenau WH, Cutler CS, et al. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24:35–43
  34. Gillemin K, Krasnow MA. The hypoxic response: huffing and HIFing. Cell Death Differ. 1997;89:9–12
  35. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary over a physiologically relevant range of O2 tension. Am J Physiol. 1996;271:C1172–C1180
  36. Höckel M, Schlenger K, Aral B, Mitze M, Shäffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advancer cancer of the uterine cervix. Cancer Res. 1996;56:4509–4515
  37. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond). 1996;379:88–91
  38. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond). 1992;359:843–845
  39. Chao C, Bosch WR, Mutic S, Lewis JS, Dehdashti FD, Mintun MA, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:1171–1182
  40. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2006;47:989–998
  41. Dearling JLJ, Lewis JS, Mullen GED, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure–activity relationships. J Biol Inorg Chem. 2002;7:249–259
  42. Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GED. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem. 2002;45:1420–1431
  43. Fricke E, Mchtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2003;30:607–611
  44. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Sooryanarayana V, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412:822–826
  45. Swinnen JV, Roskams T, Joniau S, Van H, Poppel R, Oyen L, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer. 2002;98:19–22
  46. Welsh JB, Sapinosa LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001;61:5974–5978
  47. Menendez JA, Lupu R. Oncologic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. Curr Opin Clin Nutr Metab Care. 2006;9:346–357
  48. Alo PL, Visca P, Trombetta G, Mangoni A, Lenti L, Monaco S, et al. Fatty acid synthase (FAS) predictive strength in poly differentiated early breast carcinomas. Tumori. 1999;85:35–40
  49. Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer. 1996;77:474–482
  50. Gansler TS, Hardman W, HD A, Schaffel S, Hennigar RA. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Human Pathol. 1997;28:686–692
  51. Rashid A, Pizer ES, Moga M, Milgraum LZ, Zahurak M, Pasternack GR, et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol. 1997;150:201–208
  52. Wang Y, Kuhajda FP, Li JN, Pizer ES, Han WF, Sokoll LJ, et al. Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett. 2001;167:99–104
  53. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003;1:707–715
  54. Takahiro T, Shinichi K, Toshimitsu S. Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res. 2003;9:2204–2212
  55. Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science. 2000;288:2379–2381

☆ This work was supported by the United States Department of Defense (PC040435) and fellowship support from a National Institutes of Health NRSA (F32CA110422-03).

PII: S0969-8051(07)00306-X

doi: 10.1016/j.nucmedbio.2007.11.012

Nuclear Medicine and Biology
Volume 35, Issue 3 , Pages 273-279 , April 2008

Article Tools

* Image Usage & Resolution